A pilot study exploring the efficacy and safety of herbal medicine on Korean obese women with metabolic syndrome risk factors: Double blinded, randomized, multicenter, placebo controlled study protocol clinical trial

被引:0
|
作者
Kim, Hyun-ju [1 ]
Ko, Youme [2 ,3 ]
Kim, Hojun [4 ]
Cha, Yun-Yeop [5 ]
Jang, Bo-Hyoung [2 ,3 ]
Song, Yun-Kyung [6 ]
Ko, Seong-Gyu [2 ,3 ]
机构
[1] Gachon Univ, Oriental Med Res Inst, Coll Korean Med, Seong Nam Si, South Korea
[2] Kyung Hee Univ, Dept Korean Prevent Med, Grad Sch, Seoul, South Korea
[3] Kyung Hee Univ, Inst Safety & Effectiveness Evaluat Korean Med, Seoul, South Korea
[4] Dongguk Univ, Dept Korean Rehabil Med, Coll Korean Med, Seoul, South Korea
[5] Sang Ji Univ, Dept Korean Rehabil Med, Coll Korean Med, Wonju, South Korea
[6] Gachon Univ, Dept Korean Rehabil Med, Coll Korean Med, 1342 Seongnamdaero, Seongnam Si 13120, Gyeonggi Do, South Korea
关键词
chowiseungcheng-tang; daesiho-tang; herbal medicines; metabolic syndrome risk factors; obesity; randomized controlled trial; OVERWEIGHT;
D O I
10.1097/MD.0000000000018955
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Obesity is associated with metabolic syndrome, a condition that increases one's risk for heart disease and other conditions. The prevalence of obesity and associated diseases have steadily increased among Korean adults. The effect of the herbal medicines Daesiho-tang (DSHT) and Chowiseungcheng-tang (CST) on obesity have been reported. The purpose of this study is to evaluate the efficacy and safety of Daesiho-tang and Chowiseungcheng-tang on obese Korean women with high risk for metabolic syndrome.Methods/design:This study is a randomized, double-blinded, placebo-controlled, multi-center, 3-arm, parallel group clinical trial. A total of 120 participants will be enrolled and randomly assigned to the Daesiho-tang group, the Chowiseungcheng-tang group, or the placebo group in a 1:1:1 ratio using an internet-based randomization system at visit 2. Each group will be administered DSHT, CST, or placebo 3 times per day for 12 weeks. The primary outcome is to evaluate the changes in mean body weight of participants in the DSHT and CST groups and compare with those in the placebo group, and determine their statistical significance, if any, after 12 weeks. The secondary outcomes are the following: changes in body fat percentage and body fat mass, changes in waist circumference, waist-to-hip ratio, and body mass index, changes in serum lipids, fasting blood sugar, blood pressure, and C-reactive proteins (CRP) levels between visit 1 and visit 5 measurements. Changes in visceral fat volume determined through abdominal computed tomography, patient-reported health outcomes surveys-the Korean version of the Obesity-related Quality of Life and the Korean version of Eating Attitudes Test.Discussion:This study will provide research methodologies for evaluating the efficacy and safety of Daesiho-tang and Chowiseungcheng-tang on obese Korean women with high risk for metabolic syndrome.Trial registration: ClinicalTrials.gov, NCT02651454. Registered on 11 January 2016.Protocol version: The final approved version of the trial protocol is V1.3.(2017.11.10).
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Effects of acupuncture on serum metabolic parameters in premenopausal obese women: study protocol for a randomized controlled trial
    Kim, Koh-Woon
    Yoo, Hye Hyun
    Cho, Jae-Heung
    Yang, Yo-Chan
    Kim, Je-In
    Kim, Song-Yi
    Park, Ji-Yeun
    Park, Hi-Joon
    Song, Mi-Yeon
    TRIALS, 2015, 16
  • [32] Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial
    Fang, Rui
    Hu, Hua
    Zhou, Yue
    Wang, Shanshan
    Mei, Zhigang
    She, Ruining
    Peng, Xiwen
    Jiang, Qiling
    Wang, Xiangyuan
    Xie, Le
    Lin, Hongyuan
    Meng, Pan
    Zhang, Kun
    Wang, Wei
    Xie, Yao
    Liu, Litao
    Tong, Jiao
    Wu, Dahua
    Luo, Yunhua
    Liu, Chang
    Lu, Yifang
    Yu, Shangzhen
    Cheng, Shaowu
    Xu, Linyong
    Fang, Zhuyuan
    Shang, Hongcai
    Ge, Jinwen
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [33] Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial
    Sung, Won-Suk
    Jeon, Sae-Rom
    Hong, Ye-Jin
    Kim, Tae-Hun
    Shin, Seungwon
    Lee, Hyun-Jong
    Seo, Byung-Kwan
    Park, Yeon-Cheol
    Kim, Eun-Jung
    Nam, Dong-Woo
    TRIALS, 2019, 20 (01)
  • [34] Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial
    Won-Suk Sung
    Sae-Rom Jeon
    Ye-Jin Hong
    Tae-Hun Kim
    Seungwon Shin
    Hyun-Jong Lee
    Byung-Kwan Seo
    Yeon-Cheol Park
    Eun-Jung Kim
    Dong-Woo Nam
    Trials, 20
  • [35] Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study
    Sengupta, Krishanu
    Mishra, Atmatrana T.
    Rao, Manikeswar K.
    Sarma, Kadainti V. S.
    Krishnaraju, Alluri V.
    Trimurtulu, Golakoti
    LIPIDS IN HEALTH AND DISEASE, 2012, 11
  • [36] Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study
    Krishanu Sengupta
    Atmatrana T Mishra
    Manikeswar K Rao
    Kadainti VS Sarma
    Alluri V Krishnaraju
    Golakoti Trimurtulu
    Lipids in Health and Disease, 11
  • [37] ASF (a Compound of Traditional Chinese Medicine) in the treatment of patients with alcohol dependence Study protocol of a randomized, double-blinded, placebo-controlled clinical trial
    Liang, Xianting
    Hu, Xiaoyu
    Zhang, Xia
    Fu, Hongfang
    MEDICINE, 2020, 99 (52)
  • [38] Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial
    Liu, Meifang
    Di, Yuan Ming
    Zhang, Lei
    Yang, Lihong
    Zhang, La
    Chen, Junhui
    Wang, Ruobing
    Xie, Xiaoning
    Lan, Fang
    Xie, Liping
    Huang, Juan
    Zhang, Anthony Lin
    Xue, Charlie Changli
    Liu, Xusheng
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [39] Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial
    Sun, Yuanlong
    Hu, Na
    Chen, Gaofeng
    Wang, Yanjie
    Hu, Yiyang
    Ge, Maojun
    Zhao, Yu
    TRIALS, 2022, 23 (01)
  • [40] Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial
    Li, Jiansheng
    Yu, Xue-qing
    Xie, Yang
    Yang, Shu-guang
    Zhao, Limin
    Zhou, Miao
    Meng, Yong
    FRONTIERS IN PHARMACOLOGY, 2022, 13